

FORM PTO-1390 MODIFIER	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER 3687-150
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) 10/563,288	
INTERNATIONAL APPLICATION NO. PCT/IB2004/002204	INTERNATIONAL FILING DATE 5 July 2004	PRIORITY DATE CLAIMED 18 July 2003	
TITLE OF INVENTION PEPTIDO-MIMETIC COMPOUNDS CONTAINING RGD SEQUENCE USEFUL AS INTEGRIN INHIBITORS, AND INTERMEDIATES THEREOF			
APPLICANT(S) FOR DO/EO/US SCOLASTICO ET AL.			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:			
<p>1. <input type="checkbox"/> This is a FIRST submission of items concerning a submission under 35 U.S.C. 371.</p> <p>2. <input checked="" type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a submission under 35 U.S.C. 371.</p> <p>3. <input type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</p> <p>4. <input type="checkbox"/> The U.S. has been elected (Article 31).</p> <p>5. A copy of the International Application as filed (35 U.S.C. 371(c)(2)). <ul style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto (pages specification, claims & abstract (claims), sheets drawings). b. <input type="checkbox"/> has been communicated by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). </p> <p>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(3)) <ul style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto (pages specification, claims & abstract (claims), sheets drawings, page Certificate of Translation). b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). </p> <p>7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ul style="list-style-type: none"> a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. </p> <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. a. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). <ul style="list-style-type: none"> b. <input type="checkbox"/> Declaration was submitted to the International Bureau during International Phase (see copies of Declaration (page Form PCT/RO/101 and Form PCT/IB/371 and first page of printed publication acknowledging receipt thereof attached). </p> <p>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p>			
Items 11 To 20 below concern document(s) or information included: <ul style="list-style-type: none"> 11. <input type="checkbox"/> An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included. 13. a. <input type="checkbox"/> A FIRST preliminary amendment. b. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 14. <input type="checkbox"/> An Application Data Sheet under 37 C.F.R. § 1.76. 15. <input type="checkbox"/> A substitute specification. 16. <input type="checkbox"/> A change of power of attorney and/or address letter. 17. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 37 CFR 1.821-1.825. 18. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4). 19. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4). 20. <input checked="" type="checkbox"/> Other items or information. RESPONSE TO NOTIFICATION TO COMPLY; COPY OF NOTIFICATION TO COMPLY 			

U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) 10/563,288	INTERNATIONAL APPLICATION NO. PCT/IB2004/002204	ATTORNEY'S DOCKET NUMBER 3687-150				
<input checked="" type="checkbox"/> The following fees are submitted:						
BASIC NATIONAL FEE (37 C.F.R. 1.492(a)(1)-(5):						
21. <input type="checkbox"/> Basic national fee	\$300.00 (1631)/\$150.00 (2631)	\$				
22. <input type="checkbox"/> Examination Fee	\$0 (1643/2643)	\$				
	\$200.00 (1633)/\$100.00 (2633)					
23. <input type="checkbox"/> Search Fee	\$0 (1640/2640)	\$				
	\$100 (1641)/\$50 (2641)					
	\$400 (1642)/\$200 (2642)	\$				
	\$500.00 (1632)/\$250.00 (2632)					
TOTAL OF ABOVE CALCULATIONS						
\$ 0.00						
<input type="checkbox"/> Additional fee for specification and drawings filed in paper over 100 sheets (excluding sequence listing or computer program listing filed in an electronic medium). The fee is \$250 for each additional 50 sheets of paper or fraction thereof.						
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof (round up to a whole number)	RATE			
0 -100	0 /50 =	0.00	\$ 0.00 (1681) \$0.00 (2681)	\$		
Surcharge of \$130.00 (1617)/\$65.00 (2617) for furnishing the oath or declaration later than <input type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. 1.492(e)).						
CLAIMS	NUMBER FILED	# EXTRA	RATE			
Total Claims	36	minus 36 =	0 X	\$50.00 (1615)/ \$25.00 (2615)	\$	
Independent Claims	2	minus 3 =	0 X	\$200.00 (1614)	\$100.00 (2614)	\$
MULTIPLE DEPENDENT CLAIMS(S) (if applicable)			\$360.00 (1616)/\$180.00 (2616)		\$ 0.00	
Petition is hereby made to extend the current due date so as to cover the filing date of this paper and attachment(s): One Month Extension \$120.00 (1251)/\$60.00 (2251); Two Month Extensions \$450.00 (1252)/\$225.00 (2252); Three Month Extensions \$1020.00 (1253)/\$510.00 (2253); Four Month Extensions \$1590.00 (1254)/\$795.00 (2254)					\$ 0.00	
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.						
Processing fee of \$130.00 (1618) , for furnishing the English Translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. 1.492(f)).					+ 0.00	
					TOTAL NATIONAL FEE = \$ 0.00	
Fee for recording the enclosed assignment (37 C.F.R. 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 C.F.R. 3.28, 3.31). \$40.00 (8021) per property					+ \$ 0.00	
Fee for Petition to Revive Unintentionally Abandoned Application; \$1500.00 (1453) / \$750.00 (2453)					\$ 0.00	
					TOTAL FEES ENCLOSED = \$ 0.00	
					Amount to be: refunded: \$	
U.S. Application No.10/563,288; Atty Docket No.3687-150					Amount to be: Charged: \$	
a. <input type="checkbox"/> A check in the amount of \$0.00 to cover the above fees is enclosed.						
b. <input type="checkbox"/> Please charge my Deposit Account No. 14-1140 in the amount of \$ _____ to cover the above fees. A duplicate copy of this form is enclosed.						
c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-1140. A <u>duplicate</u> copy of this form is enclosed.						
d. <input type="checkbox"/> CREDIT CARD PAYMENT FORM ATTACHED.						
CORRESPONDENCE ADDRESS						
Direct all correspondence to:						
<input checked="" type="checkbox"/> Customer Number: 23117 <small>Type Customer Number here</small>						
 Gary R. Tanigawa NAME						
Telephone: (703) 816-4000 GRT:ap			43,180 July 6, 2006 REGISTRATION NUMBER Date			



UNITED STATES PATENT AND TRADEMARK OFFICE

APC
3687-150
Page 1 of 2

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
PO Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
10/563,288	Carlo Scolastico	3687-150
INTERNATIONAL APPLICATION NO.		
PCT/IB04/02204		
I.A. FILING DATE	PRIORITY DATE	
07/05/2004	07/18/2003	
CONFIRMATION NO. 4382		
371 FORMALITIES LETTER		
OC000000018734839		

23117
NIXON & VANDERHYE, PC
901 NORTH GLEBE ROAD, 11TH FLOOR
ARLINGTON, VA 22203
DOCKETED
MATTER # 3687-150
DATE 5/10/06
E DATE Jul 10, 2006
FINAL DEADLINE Dec 10, 2006
DOCKETED BY BAG/5

Date Mailed: 05/10/2006

**NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c). Applicant must provide an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment specifically directing its entry into the application and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000).
- A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

Applicant is cautioned that correction of the above items may cause the specification and drawings page count to exceed 100 pages. If the specification and drawings exceed 100 pages, applicant will need to submit the required application size fee.

For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- For Rules Interpretation, call (571) 272-0951
- For Patentin Software Program Help, call Patent EBC at 1-866-217-9197 or directly at 703-305-3028 / 703-308-6845 between the hours of 6 a.m. and 12 midnight, Monday through Friday, EST.
- Send e-mail correspondence for Patentin Software Program Help @ ebc@uspto.gov

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

BARBARA A CAMPBELL

Telephone: (703) 308-9140 EXT 217

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
10/563,288	PCT/IB04/02204	3687-150

FORM PCT/DO/EO/922 (371 Formalities Notice)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

SCOLASTICO et al.

Appln. No. 10/563,288

Filed: January 4, 2006

Confirmation No. 4382

Atty. Ref.: 3687-150

T.C. / Art Unit: Not Known

Examiner: Not Known

FOR: PEPTIDO-MIMETIC COMPOUNDS CONTAINING RGD SEQUENCES USEFUL
AS INTEGRIN INHIBITORS, AND INTERMEDIATES THEREOF

* * *

RESPONSE TO NOTIFICATION TO COMPLY

July 6, 2006

Hon. Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In response to the Notification to Comply mailed June 10, 2006 (copy attached), consideration of the following remarks is respectfully requested. After a careful review of the specification, drawings, and claims, it is clear that a Sequence Listing is not required because no nucleotide or amino acid sequence in accordance with 37 CFR § 1.821 et seq. is disclosed in this application.

There are peptido-mimetic compounds disclosed herein of three amino acids (Arg-Gly-Asp). But no sequence of at least four amino acids is disclosed, and only an amino acid sequence of the latter length requires submission of a Sequence Listing.

Applicants earnestly solicit an early and favorable examination on the merits.

Respectfully submitted,

NIXON & VANDERHYE P.C.

By: 

Gary R. Tanigawa
Reg. No. 43,180

901 North Glebe Road, 11th Floor
Arlington, VA 22203-1808
Telephone: (703) 816-4000
Facsimile: (703) 816-4100